MediPharm Labs wins UK regulatory clearance for metered-dose cannabis inhaler
The Canadian firm's achievement marks a technical milestone as UK medical cannabis market consolidates around standardized delivery systems.
FILE — statehouse · B.D. Gilfry / CC BY-SA 2.0MediPharm Labs has cleared a European regulatory hurdle with approval of its metered-dose cannabis system in the United Kingdom, according to a Markets Business Insider report published November 5. The milestone signals incremental maturation of the UK's medical cannabis framework, which has permitted licensed production and supply since 2018 but remains tightly controlled.
The timing coincides with accelerating market infrastructure on the ground: a major UK pharmacy chain launched a medical cannabis service in mid-November, while U.S. inhalation brand Airo and multiple Canadian producers—Canopy Growth, Tilray, and others—have established or expanded UK supply operations in recent months. Regulatory standardization around delivery devices could reduce friction for licensed pharmacies and physicians evaluating product options.
Watch whether MediPharm's approval catalyzes broader adoption of metered-dose systems among UK licensed wholesalers and whether other device makers pursue similar regulatory pathways. Concurrently, the UK's pending bans on THCA and HHC (flagged in early November) could narrow the product portfolio available to medical and recreational channels alike.
Original report: markets.businessinsider.com ↗